Pulmonx Corporation reported a 15% increase in worldwide revenue to $20.4 million for the third quarter of 2024, with U.S. revenue up 17% to $13.8 million. The company maintained a gross margin of 74%.
Worldwide revenue reached $20.4 million, a 15% increase year-over-year.
U.S. revenue grew by 17% to $13.8 million.
Gross margin remained consistent at 74%.
Net loss was $14.1 million, or $0.36 per share.
Pulmonx continues to expect revenue for the full year 2024 to be in the range of $81 million to $84 million. The Company now expects gross margin for the full year 2024 to be approximately 74%. Pulmonx now expects total operating expenses for the full year 2024 to fall within the range of $122 million to $124 million, inclusive of approximately $22 million of non-cash stock-based compensation.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance